• R. Parra-Medina Department of Biology, Faculty of Natural Sciences, Universidad del Rosario, 111221, Bogotá, Colombia - Research Іnstitute, Department of Pathology, Fundación Universitaria de Ciencias de la Salud, 111221, Bogotá, Colombia -Department of Pathology, Instituto Nacional de Cancerología, ESE, 110411, Bogotá, Colombia
  • C. Payán-Gómez Universidad Nacional de Colombia, Sede de La Paz, La Paz, 202010, Colombia
  • N.L. Acosta-Vega Department of Pathology, Instituto Nacional de Cancerología, ESE, 110411, Bogotá, Colombia - Grupo de Investigación en Biología del Cáncer, Instituto Nacional de Cancerología (INC), ESE, 110411, Bogotá, Colombia
  • S. Ramírez-Clavijo Department of Biology, Faculty of Natural Sciences, Universidad del Rosario, 111221, Bogotá, Colombia



CCR-7, chemokine, early onset, prostate cancer


Background: Chemokine (C-C motif) receptor 7 (CCR7) is a chemokine receptor involved in the carcinogenesis of several types of tumors due to its promoting action in epithelial-mesenchymal transition events, invasion, angiogenesis and metastasis. However, its role in prostate cancer (PCa) remains unclear. Aim: To evaluate CCR7 expression by immunohistochemistry in prostate tumors from young patients and to determine the possible relationship with the clinicopathological characteristics. Materials and Methods: We analyzed retrospectively paraffin-embedded tissue sections from 23 young PCa (≤ 55 years old) patients and evaluated the transcriptomic expression in the TCGA database. Results: Expression of CCR7 was observed in 15 cases (65%). The tissue samples from younger patients (≤ 50 years) were mostly positive in 72.7% (8/11) of cases. High grade GS (≥ 3) tumors were CCR7-positive in 71% cases. The malignant cells present in lymph nodes were CCR7 positive in 100% cases. The bioinformatic analysis showed a high CCR7 expression associated with the presence of metastasis (FC = 2.6, p = 0.03) in the Cancer Genome Atlas (TCGA) PCa cohort (PRAD). Conclusion: We showed that CCR7 expression in tumors from young patients is associated with the early onset of the disease and could also be related to lymph node metastasis.


Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–49.

Zheng Y, Lin SX, Wu S, et al. Clinicopathological characteristics of localized prostate cancer in younger men aged ≤ 50 years treated with radical prostatectomy in the PSA era: A systematic review and meta-analysis. Cancer Med 2020; 9: 6473–84.

Parra-medina R, Ramírez-Clavijo S. Cáncer de próstata de inicio temprano. ¿ Una nueva entidad ? Rev Mex Urol 2021; 81: 1–13.

Hussein S, Satturwar S, Van der Kwast T. Young-age prostate cancer. J Clin Pathol 2015; 68: 511–5. 2015-202993

Lange EM, Salinas CA, Zuhlke KA, et al. Early onset prostate cancer has a significant genetic component. Prostate 2012; 72: 147–56.

Leongamornlert DA, Saunders EJ, Wakerell S, et al. Germline DNA repair gene mutations in young-onset prostate cancer cases in the UK: Evidence for a more extensive genetic panel. Eur Urol 2019; 76: 329–37.

Lange EM, Johnson AM, Wang Y, et al. Genome-wide association scan for variants associated with early-onset prostate cancer. PLoS One 2014; 9: e93436.

Weischenfeldt J, Simon R, Feuerbach L, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013; 23: 159–70.

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov 2022; 12: 31-46.

Sokol CL, Luster AD. The chemokine system in innate immunity. Cold Spring Harb Perspect Biol 2015; 7: a016303.

Rani A, Dasgupta P, Murphy JJ. Prostate cancer: the role of inflammation and chemokines. Am J Pathol 2019; 189: 2119–37.

Ding Y, Wu H, Warden C, et al. Gene expression differences in prostate cancers between young and old men. PLOS Genet 2016; 12: e1006477.

Parra-Medina R, López-Kleine L, Ramírez-Clavijo S, et al. Identification of candidate miRNAs in early-onset and late-onset prostate cancer by network analysis. Sci Rep 2020; 10: 1–14.

Valera VA, Parra-Medina R, Walter BA, et al. microRNA expression profiling in young prostate cancer patients. J Cancer 2020; 11: 4106–14.

Hirao M, Onai N, Hiroishi K, et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000; 60: 2209–17.

Korbecki J, Grochans S, Gutowska I, et al. CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands. Int J Mol Sci 2020; 21: 7619.

Salem A, Alotaibi M, Mroueh R, et al. CCR7 as a therapeutic target in Cancer. Biochim Biophys Acta Rev Cancer 2021; 1875: 188499.

Zu G, Luo B, Yang Y, et al. Meta-analysis of the prognostic value of C-C chemokine receptor type 7 in patients with solid tumors. Cancer Manag Res 2019; 11: 1881–92.

Du R, Tang G, Tang Z, et al. Ectopic expression of CC chemokine receptor 7 promotes prostate cancer cells metastasis via Notch1 signaling. J Cell Biochem 2019; 120: 9639–47.

Maolake A, Izumi K, Natsagdorj A, et al. Tumor necrosis factor-α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation. Cancer Sci 2018; 109: 1524–31.

Zheng L, Dou X, Ma X, et al. Identification of potential key genes and pathways in enzalutamide-resistant prostate cancer cell lines: a bioinformatics analysis with data from the gene expression omnibus (GEO) database. Biomed Res Int 2020; 2020: 8341097.

Collado-Torres L, Nellore A, Kammers K, et al. Reproducible RNA-seq analysis using recount2. Nat Biotechnol 2017; 35: 319–21.

Afgan E, Baker D, van den Beek M, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. Nucleic Acids Res 2016; 44: W3–10.

Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339: 286–91.

Rizeq B, Malki MI. The Role of CCL21/CCR7 chemokine axis in breast cancer progression. Cancers 2020; 12: 1036.

Chi B-J, Du C-L, Fu Y-F, et al. Silencing of CCR7 inhibits the growth, invasion and migration of prostate cancer cells induced by VEGFC. Int J Clin Exp Pathol 2015; 8: 12533–40.

Youlin K, Weiyang H, Simin L, et al. Prostaglandin E 2 inhibits prostate cancer progression by countervailing tumor microenvironment-induced impairment of dendritic cell migration through LXR α /CCR7 pathway. J Immunol Res 2018; 2018: 1–8.

Rodríguez-Berriguete G, Fraile B, Martínez-Onsurbe P, et al. MAP kinases and prostate cancer. J Signal Transduct 2012; 2012: 1–9.

Dong Z, Bonfil RD, Chinni S, et al. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 2005; 166: 1173–86.

Rankin EB, Nam J-M, Giaccia AJ. Hypoxia: signaling the metastatic cascade. Trends Cancer 2016; 2: 295–304.

Li M, Wang YX, Luo Y, et al. Hypoxia inducible factor-1α-dependent epithelial to mesenchymal transition under hypoxic conditions in prostate cancer cells. Oncol Rep 2016; 36: 521–7.

Palayoor ST, Mitchell JB, Cerna D, et al. PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer 2008; 123: 2430–7.

Rudolfsson SH, Bergh A. Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target. Expert Opin Ther Targets 2009; 13: 219–25.

Pipinikas CP, Carter ND, Corbishley CM, et al. HIF-1α mRNA gene expression levels in improved diagnosis of early stages of prostate cancer. Biomarkers 2008; 13: 680–91.

Xiao L-J, Chen Y-Y, Lin P, et al. Hypoxia increases CX3CR1 expression via HIF-1 and NF-κB in androgen-independent prostate cancer cells. Int J Oncol 2012; 41: 1827–36.

Wilson JL, Burchell J, Grimshaw MJ. Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res 2006; 66: 11802–7.

Li Y, Qiu X, Zhang S, et al. Hypoxia-induced CCR7 expression via HIF-1α and HIF-2α correlates with migration and invasion in lung cancer cells. Cancer Biol Ther 2009; 8: 322–30.

Basheer HA, Pakanavicius E, Cooper PA, et al. Hypoxia modulates CCR7 expression in head and neck cancers. Oral Oncol 2018; 80: 64–73.

Cheng S, Han L, Guo J, et al. The essential roles of CCR7 in epithelial-to-mesenchymal transition induced by hypoxia in epithelial ovarian carcinomas. Tumor Biol 2014; 35: 12293–8.




How to Cite

Parra-Medina, R., Payán-Gómez, C., Acosta-Vega, N., & Ramírez-Clavijo, S. (2023). EXPRESSION OF CHEMOKINE (C-C MOTIF) RECEPTOR 7 IN PROSTATE CANCER TISSUE OF YOUNG PATIENTS AND IN METASTATIC CANCER CELLS. Experimental Oncology, 44(2), 137–141.



Original contributions

Most read articles by the same author(s)